Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.39 |
| ▸ | TAF1 | P21675 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28495832 | 0.72 | METAP2 (0.37) | BRD4 | |
| SCHEMBL24471203 | 0.72 | BRD4 (0.39) | BRD4KAT2BBRD9TAF1BRPF1 | |
| SCHEMBL17559135 | 0.71 | KAT2B (0.50) | KAT2BKMT2A | |
| SCHEMBL31091769 | 0.71 | KAT2B (0.50) | KAT2BKMT2A | |
| SCHEMBL25201884 | 0.70 | NPBWR1 (0.47) | BRD4KMT2A | |
| SCHEMBL29985233 | 0.68 | PARG (0.44) | KAT2B | |
| SCHEMBL17571632 | 0.67 | KAT2B (1.00) | KAT2B | |
| SCHEMBL15069525 | 0.67 | BRD4 (0.44) | BRD4KMT2A | |
| SCHEMBL15788366 | 0.67 | PARG (0.37) | KAT2BBRD9KMT2A | |
| SCHEMBL25226425 | 0.66 | CCR8 (0.42) | CCR8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10155764-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3189049-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2016036954-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097052-A1 | BROMODOMAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885KAT2B 212/4885BRD9 14/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885KAT2B 212/4885BRD9 14/4885 |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | BRD4 558/4885KAT2B 41/4885BRD9 1259/4885 |
| US-10155764-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC1 | BRD4 558/4885KAT2B 41/4885BRD9 1259/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885KAT2B 212/4885BRD9 14/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885KAT2B 212/4885BRD9 14/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885KAT2B 212/4885BRD9 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.